Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $100.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
